I-Flow Announces First Quarter 2007 Regional Anesthesia Sales Increased 34 Percent

LAKE FOREST, Calif. -- I-Flow Corporation announces financial results for the first quarter of 2007, highlighted by a 34 percent increase in revenue in its regional anesthesia business to a first-quarter record of $19.1 million compared to $14.3 million for the first quarter of 2006, and a 22 percent increase in total revenue from continuing operations to $24.3 million compared to $19.9 million in the prior year quarter.

"This outstanding performance by our regional anesthesia business reflected another quarter of strong sales of our proprietary ON-Q® products for relieving post-surgical pain without narcotics,” said Donald M. Earhart, chairman, president, and CEO. “Clinical study after clinical study has confirmed the efficacy of ON-Q across a wide range of surgical procedures. Just two weeks ago we announced encouraging preliminary results from an ongoing study of the effects of ON-Q PainBuster® with ON-Q SilverSoakerTM Antimicrobial Catheter in reducing surgical site infections in colorectal surgery. We initiated this prospective human study based on a recent infection meta-analysis of 50 studies encompassing 4,030 patients which revealed a lower rate of surgical site infections with ON-Q than standard pain relief treatments. We also reported on the first pediatric study highlighting the positive outcomes seen when ON-Q is used to treat pain after surgery in young heart patients. In addition, an independent pain relief meta-analysis published in December 2006 of 44 different randomized clinical trials involving 2,141 patients confirmed the efficacy of continuous wound catheters that deliver local anesthetic, including ON-Q, for post-surgical pain relief.”

Earhart continued, "The accumulation of such compelling clinical evidence supporting the benefits of ON-Q is encouraging more and more hospitals, ambulatory surgery centers, surgeons, anesthesiologists and their patients to use our products, and enhancing our confidence that ON-Q has the potential to replace narcotics as the standard of care in the multi-billion dollar post-surgical pain relief market. During the first quarter, we stepped up our efforts to take advantage of this outstanding long-term growth opportunity by beginning once again to expand our sales force and marketing activities. We had originally planned to increase spending in these critical areas later this year, following the anticipated closing of the sale of our InfuSystem subsidiary for $140 million, but we have decided to respond to the unprecedented interest in our therapy by accelerating the timeline and significantly increasing sales and marketing support for ON-Q now.”

Source: I-Flow Corporation

Share this article: Email, Slashdot, Digg, Del.icio.us, Yahoo!MyWeb, Windows Live Favorites, Furl
Add this article feed to: RSS, My Yahoo, Newsgator, Bloglines